Atrial Fibrillation and Ischemic Stroke With the Amyloidogenic V122I Transthyretin Variant Among Black Americans

Senthil Selvaraj, Brian Claggett, Masatoshi Minamisawa, B. Gwen Windham, Lin Y. Chen, Riccardo M. Inciardi, Joel N. Buxbaum, Thomas H. Mosley, Amil M. Shah, Scott D. Solomon

Research output: Contribution to journalLetterpeer-review

10 Scopus citations
Original languageEnglish (US)
Pages (from-to)89-91
Number of pages3
JournalJournal of the American College of Cardiology
Issue number1
StatePublished - Jul 6 2021

Bibliographical note

Funding Information:
The ARIC study has been funded in whole or in part with federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services (contract numbers HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I, and HHSN268201700005I). Additionally, this research was supported by R01 HL126637 (to Dr. Chen), and R01HL135008, R01HL143224, R01HL150342, R01HL148218, and K24HL152008 (to Dr. Shah). Dr. Selvaraj has received research support from the Doris Duke Charitable Foundation (Physician Scientist Fellowship Award 2020061), the Measey Foundation, Institute for Translational Medicine and Therapeutics (Junior Investigator Preliminary/Feasibility Grant Program award and Translational Bio-Imaging Center award), and the American Society of Nuclear Cardiology (Institute for the Advancement of Nuclear Cardiology award). Dr. Minamisawa has received support from the Japanese Circulation Society, the Japanese Society of Echocardiography, and the Uehara Memorial Foundation Overseas Research Fellowship. Dr. Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, NIH/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, and Theracos; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, and American Regent. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors thank the staff and participants of the ARIC study for their important contributions.

Cite this